and long-acting GLP-1 RAs, including exenatide once-weekly, liraglutide, albiglutide, dulaglutide, and semaglutide, known for providing more consistent glycemic control 48,49
10.1016/j.mtchem.2023.101894 20 SabatiniM
As competition intensifies and new formulations move through regulatory and clinical milestones, the GLP-1 market is poised to remain a major driver of growth and innovation across the broader pharmaceutical industry
It must be applied in a thin layer at night, on the face
Most patients enter an initial intensive phase (3-6 months) focused on stabilization and significant symptom reduction, followed by a personalized, long-term maintenance plan that helps prevent relapse and supports continued wellness
S., Whiteman, M., Yang, H., Jones, D